NovelStem International Corp. develops novel diagnostic technology that can predict patients resistance to chemotherapy allowing for cancer treatments and the potential to reduce resistance to chemotherapy. The company is headquartered in Boca Raton, Florida. The firm's primary assets are NewStem Ltd (NewStem) and NetCo Partners (NetCo). NewStem focuses on the development and commercialization of diagnostic technology that can predict patients’ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is principally focused on utilizing proprietary human Pluripotent Stem Cells (hPSCs) and Haploid human Pluripotent Stem Cells (HhPSCs) in the development of diagnostic and therapeutic products in oncology. Its NewStem Software Diagnostic Device (NSDD) is a bioinformatics-based software medical device platform that provides oncologists with information regarding the presence of mutations in tumors, which may confer patient resistance to certain anti-cancer drugs. NetCo is a media business interest which owns Net Force, a book publishing franchise.
Follow-Up Questions
Who is the CEO of Novelstem International Corp?
Mr. Jan Loeb is the Executive Chairman of the Board of Novelstem International Corp, joining the firm since 2018.
What is the price performance of NSTM stock?
The current price of NSTM is $0.0194, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Novelstem International Corp?
Novelstem International Corp belongs to Biotechnology industry and the sector is Health Care
What is Novelstem International Corp market cap?
Novelstem International Corp's current market cap is $911.3K
